返回
Northwest Biotherapeutics Inc（NWBO）價格
NWBO 股價走勢圖
NWBO 收益
Northwest Biotherapeutics Inc
$0.3
5.93%
$0.01
收盤價：Jan 16, 16:00:00 GMT-5
$0.3
0%
$0
盤後：Jan 16, 20:00:00 GMT-5
最新獲利結果： Q4 '24
報導： 2025-03-31
歷史收益
每季
年度
EPS
收入
Earnings FAQ
NWBO 最近的每股盈餘與預期相比如何？
Northwest Biotherapeutics Inc NWBO 上一季度的收入表現如何？
Northwest Biotherapeutics Inc 的收入預期是多少？
Northwest Biotherapeutics Inc 的盈利品質評分是多少？
Northwest Biotherapeutics Inc 何時發布財報？
Northwest Biotherapeutics Inc 的預期收益是多少？
Northwest Biotherapeutics Inc 是否超出收益預期？
關鍵數據
前收市價
$0.2832
開盤價
$0.2898
當日範圍
$0.2826 - $0.301
52週區間
$0.17 - $0.48
交易量
1.5M
平均成交量
3.8M
每股盈餘 (TTM)
-0.06
股息收益率
--
市值
$458.6M
什麼是 NWBO？
Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. The company is headquartered in Bethesda, Maryland and currently employs 25 full-time employees. The company went IPO on 2001-12-14. The firm is focused on developing personalized immune therapies for cancer. The company has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The firm's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. The company has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.